Therapeutic Areas
About Us
Contributors
Receive daily COVID-19 news

Browse

Journals
Gold
Careers

Journals
Gold
Careers
More
Login / Register

Journals
Gold
Careers
Login / Register

Login to continue

Members

Forgotten your password?

Create Account

Create your own personal healthcare feed, full of the latest content from across our divisions.

You must accept all conditions before being able to view the post

Therapeutic Area
Allergy & Immunology

Interventional Cardiology

Cardiology

Microbiology & Infectious Diseases

Dermatology

Nephrology

Diabetes

Neurology

Flagship Journal

Oncology

Gastroenterology

Radiology

General Healthcare

Reproductive Health

Hematology

Respiratory

Hepatology

Rheumatology

Innovations

Urology
January 2022
|
Innovations

EMJ Innovations 6.1 2022
About Us
Careers

Partners & Directory

Compliance

Open Access & Copyright

Contact Us
Contributors
Authors

Peer Reviewers

Submit a Paper

Editorial Board
Newsletters & Alerts

Home Dermatology Phase 2a trial of ZPL-3893787 (ZPL-389), a histamine H4 receptor antagonist,…

Phase 2a trial of ZPL-3893787 (ZPL-389), a histamine H4 receptor antagonist, for atopic dermatitis

14 June 2016 |

Related To This Subject

Beyond Aesthetics: Hyaluronic Acid Fillers as a Therapeutic Treatment

Any filler injection requires a bespoke treatment approach and a thorough anatomy knowledge to minimise procedural risks and achieve…

Venous Thromboembolism and Chronic Inflammatory Skin Conditions: Rethinking Their Connection

Data is needed when treating VTE patients with chronic inflammatory skin conditions such as a psoriasis and atopic dermatitis…

Share

More articles

Dermatology CP

A Retrospective Database Cohort Study Evaluating the Association Between Immune Suppressive Therapy and the Development of Cancer in Patients with Atopic Dermatitis Within UK Primary Care

Dermatology CP

Trichotillomania with Giant Gastric Trichobezoar in a Female Child: A Case Report

Dermatology CP

Varicella Zoster Reactivation Following mRNA Vaccination: Two Case Reports and a Review of Cutaneous Adverse Events of COVID-19 Vaccines

Featured journals

EMJ Dermatology 10 [Infographic Supplement 2] 2022 Feature Image

EMJ Dermatology 10 [Infographic Supplement 2] 2022

EMJ Dermatology 10 [Supplement 3] 2022

EMJ Dermatology 10 [Infographic Supplement 1] 2022 Feature Image

EMJ Dermatology 10 [Infographic Supplement 1] 2022

Therapeutic Area

Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Nephrology
Neurology
Oncology
Reproductive Health
Respiratory
Rheumatology
Urology

About Us

About Us
GOLD
Careers
Partners & Directory
Compliance
Open Access & Copyright
Contact Us
Events
Contributors
Newsletters & Alerts
Media Pack
FAQ

Copyright © 2022 European Medical Group LTD trading as European Medical Journal. All rights reserved. European Medical Journal is for informational purposes and should not be considered medical advice, diagnosis or treatment recommendations.

Ts & Cs Privacy Policy Cookie Policy

Website by Vibe Agency

Proud to be ISO9001 Certified.

The ISO 9001 standard is an internationally recognised standard that is based on a number of quality management principles including a strong customer focus, the management of process change, effective methods of reducing non- compliance, and the continual improvement in the quality of our services.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.